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Background: 20(S)-Protopanaxadiol 20-O-D-glucopyranoside, also called compound K (CK), exerts
antidiabetic effects that are mediated by insulin secretion through adenosine triphosphate (ATP)-sen-
sitive potassium (KATP) channels in pancreatic b-cells. However, the antidiabetic effects of CK may be
limited because of its low bioavailability.
Methods: In this study, we aimed to enhance the antidiabetic activity and lower the toxicity of CK by
including it with b-cyclodextrin (CD) (CD-CK), and to determine whether the CD-CK compound
enhanced pancreatic islet recovery, compared to CK alone, in an alloxan-induced diabetic zebraﬁsh
model. Furthermore, we conﬁrmed the toxicity of CD-CK relative to CK alone by morphological changes,
mitochondrial damage, and TdT-UTP nick end labeling (TUNEL) assays, and determined the ratio be-
tween the toxic and therapeutic dose for both compounds to verify the relative safety of CK and CD-CK.
Results: The CD-CK conjugate (EC50 ¼ 2.158mM) enhanced the recovery of pancreatic islets, compared to
CK alone (EC50 ¼ 7.221mM), as assessed in alloxan-induced diabetic zebraﬁsh larvae. In addition, CD-CK
(LC50 ¼ 20.68mM) was less toxic than CK alone (LC50 ¼ 14.24mM). The therapeutic index of CK and CD-CK
was 1.98 and 9.58, respectively.
Conclusion: The CD-CK inclusion complex enhanced the recovery of damaged pancreatic islets in diabetic
zebraﬁsh. The CD-CK inclusion complex has potential as an effective antidiabetic efﬁcacy with lower
toxicity.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
20(S)-Protopanaxadiol 20-O-D-glucopyranoside, also called
compound K (CK, Fig. 1A), is a minor ginsenoside of Panax ginseng
[1]. Compund K is the main metabolite obtained through
biotransformation by human intestinal bacteria after the oral
administration of protopanaxadiol (PPD)-ginsenosides [2e4];
therefore, CK is manufactured by the biodeglycosylation of PPD-nology, Department of Oriental M
est Medical Science, Kyung Hee Un
anjae@khu.ac.kr (T.H. Kang).
ht  2016, The Korean Society of G
d/4.0/).ginsenosides [5]. Compound K has anticancer [6e8], anti-
inﬂammatory [9e12], and antidiabetic activity related to
insulin secretion through adenosine triphosphate (ATP)-sensitive
potassium (KATP) channels [13]. Compound K has low solubility
in water; therefore, these bioactivity effects may be limited and
many investigators have focused on increasing its solubility.
For example, CK including in glycol chitosan increased its solubi-
lity and antitumor activity [14]. In addition, CK has been includededicine Biotechnology, Kyung Hee University, 1732, Deogyeong-daero, Giheung-gu,
iversity, 1732, Deogyeong-daero, Giheung-gu, Yongin-si, Gyeonggi-do, 17104, Korea.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
Fig. 1. The molecular structure of the compounds used in the study. (A) 20(S)-protopanaxadiol 20-O-D-glucopyranoside (i.e., compound K). (B) b-cyclodextrin.
J Ginseng Res 2017;41:103e112104in b-cyclodextrin (CD, Fig. 1B) to improve its bioavailability [15]. b-
Cyclodextrin is a natural cyclic oligosaccharide formed from the
enzymatic degradation of starch by bacteria; it has a hydrophilic
outer surface and a hydrophobic central cavity that can be used to
solubilize compounds with less polarity [16]. Therefore, CD is
widely used to improve the dissolution of less polar compounds
and drugs [17,18]. In addition, CD is nontoxic and has good stability
[19e21]. A systematic assessment of CK toxicity has not been re-
ported; however, CK is cytotoxic against tumor cells, and sub-
chronic toxicity studies [22,23] suggest it may be hepatotoxic. In
this study, we aimed to enhance the antidiabetic activity and lower
the toxicity of CK by including it with CD (CD-CK), and to deter-
mine whether the CD-CK compound enhances pancreatic islet
recovery, compared to CK alone, in an alloxan-induced diabetic
zebraﬁsh model. To investigate this mechanism, we used glime-
piride (GLM) and diazoxide, which affect the KATP channels.
Furthermore, we conﬁrmed the toxicity of CD-CK relative to
CK alone and determined the ratio between the toxic and thera-
peutic dose for both compounds to verify the relative safety of CK
and CD-CK.
2. Materials and methods
2.1. Reagents and equipment
b-Cyclodextrin was purchased from Tokyo Chemical Industry
Co., Ltd. (Tokyo, Japan) and 20(S)-protonaxadiol 20-O-D-glucopyr-
anoside (compound K) was obtained from Climax Biotech Co., Ltd.
(Chengdu, China). Alloxan monohydrate and sea salts were ob-
tained from Sigma Chemical Co. (St. Louis, MO, USA), and 2-(N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG)
was purchased from Invitrogen Co., Ltd. (Grand Island, NY, USA).
Glimepiride and diazoxide were purchased from Cayman Chemical
Co. (Ann Arbor, MI, USA) and Santa Cruz Biotechnology Inc. (Dallas,
TX, USA), respectively. Fluorescence microscopy was conducted
using an Olympus 1X70 microscope (Olympus Co., Ltd., Tokyo,
Japan). Focus Lite (Focus Co, Daejeon, Korea) and Image J (National
Institutes of Health, Bethesda, MD, USA) software were used for
image analysis.
2.2. b-Cyclodextrin-compound K (CD-CK) inclusion complex
Compound K (CK) (1.3 mg) was added to 2 mL of 10 mM CD in
water solution and stirred for 20 h. After equilibrium, the sample
was ﬁltered through a 0.45-mm membrane ﬁlter. Compound K at
1mM in dimethyl sulfoxide (DMSO) was prepared as the reference
sample.2.3. Turbidity study
Turbidity changes, based on the molar ratio of CD to CK (i.e., 0:1,
1:1, 3:1, 5:1, 10:1), were determined by photography after 20 h of
stirring at room temperature.
2.4. Zebraﬁsh maintenance and egg collection
Adult zebraﬁsh were maintained in a zebraﬁsh S-type housing
system [1500 mm (width)  400 mm (depth)  2050 mm (height);
Genomic Design Bioengineering Co., Daejeon, Korea]. Two pairs of
zebraﬁsh were placed in a spawning box overnight. The next day,
the zebraﬁsh initiated spawning after a 30-min light period.
Zebraﬁsh eggs were collected 3 h postfertilization (hpf) and incu-
bated in Petri dishes in a 0.03% sea salt solution. Embryos were
maintained in a 14-h light:10-h dark photoperiod in an incubator at
28.5C. Zebraﬁsh were cared for in accordance with standard
zebraﬁsh protocols approved by the Animal Care and Use Com-
mittee of Kyung Hee University (Seoul, Korea).
2.5. Compound K and CD-CK efﬁcacy on alloxan-induced pancreatic
islet damage zebraﬁsh larvae
We evaluated CK and CD-CK using zebraﬁsh larvae. Wild-type
zebraﬁsh larvae 5 d postfertilization (dpf) were placed into a 96-
well plate. The larvae were exposed to 25mM 2-NBDG for 12 h
and rinsed three times using 0.03% sea salt solution. To induce
pancreatic islet damage, we used alloxan at a concentration of
100mM. After 6 h of alloxan treatment, the larvae were stained for
1 hwith 25mM2-NBDG. The larvaeweremounted in 96-well plates,
and observed using ﬂuorescence microscopy. To determine the
efﬁcacy of CK, CD-CK, and GLM as a positive control, zebraﬁsh were
treated with 5mM CK, CD-CK, or GLM for 1 h, after which the larvae
were restained for 1 h with 25mM 2-NBDG and observed under
ﬂuorescence microscopy. All captured images were analyzed for
pancreatic islet size and histogram using Focus Lite and Image J
Software. Before and after treatment, we analyzed pancreatic islet
size via images. All values are expressed as the size change value,
based on the following equation: size change value ¼ post-treat-
ment pancreatic islet size e pretreatment pancreatic islet size.
2.6. The 50% effective concentration
Zebraﬁsh were treated with nine different concentrations (i.e.,
0.05mM, 0.1mM, 0.5mM, 1.0mM, 2.5mM, 5.0mM, 7.5mM, 10.0mM, and
15.0mM) of CK alone or CD-CK. The 50% effective concentration
(EC50) values were calculated by nonlinear regression using
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Diego, CA, USA).2.7. Action of diazoxide on alloxan-induced pancreatic islet-
damaged zebraﬁsh larvae
Wild-type zebraﬁsh larvae 5 dpf were divided into the following
seven groups: normal, 100mM alloxan, 25mM diazoxide as a nega-
tive control, 5mM CK, 5mM CK þ 25mM diazoxide, 5mM CD-CK, and
5mM CD-CK þ 25mM diazoxide. Zebraﬁsh larvae were treated with
25mM 2-NBDG for 12 h. To damage the pancreatic islets, zebraﬁsh
larvae were treated with 100mM alloxan and stained with 25mM 2-
NBDG for 1 h. Fluorescence microscopy images were then obtained.
After ﬁrst capture, zebraﬁsh larvaewere treatedwith CK and CD-CK
with diazoxide. Second images were captured by ﬂuorescence
microscopy. All images were analyzed using Focus Lite and Image J
software.2.8. Identiﬁcation of the development of toxicity related to CK and
CD-CK
Twenty zebraﬁsh embryos were chosen to undergo treatment
for toxic testing. Embryos were placed in six-well plates, which
were incubated under temperature control at 28.5C and a 14-h
light:10-h dark photoperiod. Sixteen treatments were used: con-
trol, CD, CD-CK, and GLM at 5.0mM, 10.0mM, 15.0mM, 20.0mM and
25.0mM concentrations, respectively. The embryos were observed
under microscopy at 2 d post-treatment (dpt) and dead embryos
were recorded. We evaluated the survival rate, heartbeat, and body
length.2.9. Efﬁcacy of CK and CD-CK in expressing enhanced green
ﬂuorescent protein fused to the mitochondrial localization sequence
of zebraﬁsh COXVIII
Enhanced green ﬂuorescent protein (EGFP) fused to the mito-
chondrial localization sequence (MLS) of zebraﬁsh COXVIII (MLS-
EGFP) zebraﬁsh larvae were obtained from Genomic Design
Bioengineering Co. (Daejeon, Korea). The MLS-EGFP zebraﬁsh
larvae at 3 dpf were treated with CK and CD-CK at a 20mM con-
centration. After 48 h treatment, MLS-EGFP zebraﬁsh larvae were
observed under ﬂuorescent microscopy and all images were
analyzed using Focus Lite and Image J software.2.10. TdT-UTP nick end labeling assay
Wild-type zebraﬁsh larvae at 3 dpf were treated with 20mM CK
or CD-CK. After 48 h treatment, zebraﬁsh larvae were ﬁxed in fresh
4% paraformaldehyde in phosphate-buffered saline (PBS) with
0.05% Tween 20 (PBST) overnight at 4C, dehydrated with meth-
anol, stored overnight at 20C, and rehydrated using decreasing
concentrations of methanol in PBST. A TdT-UTP nick end labeling
(TUNEL) assay was performed using the DeadEnd Fluorometric
TUNEL System (Promega Ltd., Madison, WI, USA). Fluorescent
TUNEL-positive cells were detected and counted under a ﬂuores-
cent microscope.Fig. 2. Turbidity changes in accordance with the concentration of b-cyclodextrin (CD)
to compound K (CK).2.11. The 50% lethal concentration values of CD and CD-CK
Zebraﬁsh were treated with six different concentrations (i.e.,
5mM, 10mM, 15mM, 20mM, 25mM, and 30mM) of CD or CD-CK. The
50% lethal concentration (LC50) values were calculated by
nonlinear regression using GraphPad Prism version 5.01 software.2.12. Therapeutic index
The therapeutic index (TI) (also called the therapeutic window
or safety margin) is the ratio between the toxic dose and the
therapeutic dose of a drug. It is used to measure the relative safety
of the drug for a particular treatment. We calculated the TI by the
following equation: TI ¼ LC50/EC50.
2.13. Statistical analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (version 5.01). The data are expressed as the mean standard
error of mean and signiﬁcancewas determined using repeated one-
way analysis of variance (ANOVA) followed by Tukey’s test. The
probability level for statistical signiﬁcance was p < 0.05.
3. Results
3.1. Turbidity study
To evaluate the turbidity of CK by CD, we conﬁrmed that the vials
(1e5) had a molar ratio of CD to CK at 0:1, 1:1, 3:1, 5:1, 10:1, respec-
tively. Bubbleswereobserved invials1e4andthevials contained free
saponin in solution. Vial 5 contained a clear solution without any
bubbles and had a complete CD-CK inclusion complex (Fig. 2).
3.2. Optimal CD-CK inclusion complex
To evaluate the bioavailability of CD-CK, damaged zebraﬁsh
pancreatic islets were treated with different molar ratios of CD to CK
(0:1, 1:1, 3:1, 5:1, and 10:1) and CK in DMSO as the control.
Pancreatic islet size in the alloxan-treated group was signiﬁcantly
decreased by 8.81-fold (p ¼ 0.0112), compared to the normal group.
The CK-treated group had a 1.72-fold increase in the islet size
(p¼ 0.0045), compared to the alloxan-treated group. Pancreatic islet
size in the CD:CK [0:1]- and [1:1]-treated groups was increased by
0.95-fold (p ¼ 0.2700) and 1.16-fold (p ¼ 0.0735), respectively,
compared to the alloxan-treated group. In addition, the CD:CK [3:1]-
, [5:1]-, and [10:1]-treated groups had a signiﬁcant increase in the
pancreatic size of 1.19-fold (p ¼ 0.0303), 2.09-fold (p ¼ 0.0002), and
2.92-fold (p ¼ 0.0112), respectively (Figs. 3A and 3C).
To investigate the histogram of pancreatic islets, we used Image
J software. The histogram is a count of pixel values that indicate
ﬂuorescence intensity (green color) ranging from level 0 to level
255. The green level in the alloxan-treated group (the mean count
Fig. 3. The effects of various ratios of b-cyclodextrin included in compound K (CD-CK) in alloxan-induced pancreatic islet-damaged zebraﬁsh. (A) The size change in the pancreatic
islets in each group. (B) Fluorescence intensity analysis of the zebraﬁsh pancreatic islets. (C) Representative ﬁnal pancreatic islet images of the normal (NOR), alloxan (AX),
compound K (CK), b-cyclodextrin (CD):CK [0:1], CD:CK [1:1], CD:CK [3:1], CD:CK [5:1] and CD:CK [10:1] groups. Pancreatic islet stained with 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose. The white arrow indicates the location of pancreatic islet. Scale bar ¼ 100 mm. # p < 0.05; compared to the normal group. * p < 0.05. ** p < 0.01, and ***
p < 0.001, compared to the alloxan group.
J Ginseng Res 2017;41:103e112106of pixels ¼ 72, p ¼ 0.0162) was signiﬁcantly decreased, compared
with that of the normal group (themean count of pixels¼ 132). The
CK-treated (the mean count of pixels ¼ 117, p ¼ 0.0213) and CD:CK
[10:1]-treated groups (the mean count of pixels ¼ 128, p ¼ 0.0183)
were signiﬁcantly increased, compared to the alloxan-treated
group (Figs. 3B and 3C).3.3. The effect CK and CD-CK on alloxan-induced pancreatic islet-
damaged zebraﬁsh larvae
To evaluate the efﬁcacy of CK and CD-CK, we investigated the
pancreatic islets after alloxan treatment with GLM, CD, CK and CD-
CK at 5mM. As the positive control, GLM promoted insulin secretion
by closing KþATP channels [24]. The pancreatic islet size in the
alloxan-treated group was signiﬁcantly decreased by 8.54-fold
(p < 0.0001), compared to the normal group. The GLM-treated
group had a 2.19-fold increase in the islet size (p < 0.0001),
compared to the alloxan-treated group. The CD-treated group had a
0.87-fold increase in the pancreatic size (p ¼ 0.0121), compared to
the alloxan-treated group. In addition, the CK-treated and CD-CK-
treated groups had a 1.89-fold (p < 0.0001) and 2.36-fold(p < 0.0001) increase, respectively, in the pancreatic size, which
was signiﬁcant (Fig. 4A).
Moreover, we measured ﬂuorescence intensity under these
same treatments. The green level in the alloxan-treated group (the
mean count of pixels ¼ 72, p ¼ 0.0014) was signiﬁcantly decreased,
compared to the normal group (the mean count of pixels ¼ 130).
The GLM-treated group was signiﬁcantly increased (the mean
count of pixels ¼ 117, p ¼ 0.0037), compared to the alloxan-treated
group. The CK-treated group was increased (the mean count of
pixels ¼ 100, p ¼ 0.0818), compared to the alloxan-treated group.
The CD-CK-treated group was signiﬁcantly increased (the mean
count of pixels ¼ 132, p ¼ 0.0292), compared to the alloxan-treated
group (Fig. 4B). The CD-CK-treated group had a similar recovery
pattern as that of the GLM-treated group.3.4. The EC50 values of CK and CD-CK
To evaluate the EC50, we generated a dose-effect curve using
zebraﬁsh treated with CK and CD-CK at nine different CK and CD-
CK concentrations. The EC50 values of CK and CD-CK were calcu-
lated at 7.221mM and 2.158mM, respectively (Fig. 5).
Fig. 4. The effects of 5mM compound K (CK) and b-cyclodextrin included in compound K (CD-CK) in alloxan-induced pancreatic islet-damaged zebraﬁsh. (A) The size change in the
pancreatic islets in each group. (B) Fluorescence intensity analysis in the pancreatic islets of zebraﬁsh. (C) Representative ﬁnal pancreatic islet images of the normal (NOR), alloxan
(AX), b-cyclodextrin (b-CD), glimepiride (GLM), CK, and CD-CK groups. The pancreatic islets are stained with 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose. The
white arrow indicates the location of pancreatic islet. Scale bar ¼ 100 mm. # p < 0.05 and ### p < 0.001, compared to the normal group. * p < 0.05, ** p < 0.01, and *** p < 0.001,
compared to the alloxan group.
Y.H. Nam et al / b-cyclodextrin compound K in zebraﬁsh 1073.5. Action of diazoxide on alloxan-induced pancreatic islet-
damaged zebraﬁsh larvae
To evaluate the involvement of CK and CD-CK in pancreatic b-
cell KATP channels, we investigated pancreatic islet size after
diazoxide treatment. Diazoxide inhibits insulin secretion as a
KATP channel opener in the prediabetic and diabetic state [25].
During diazoxide treatment, the pancreatic islet size of the CK
with the diazoxide-treated group was decreased by 0.76-fold
(p ¼ 0.2437) compared to the CK-treated group. Furthermore,EC50
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Fig. 5. The dose-effect curves of compound K (CK) and b-cyclodextrin included in
compound K (CD-CK). The EC50 of CK was 7.221mM, and the EC50 of CD-CK was
2.158mM. Conc., concentration; EC50, 50% effective concentration.the CD-CK with diazoxide-treated group was signiﬁcantly
decreased by 1.25-fold (p ¼ 0.0099), compared to the CD-CK-
treated group (Fig. 6A). However, the ﬂuorescence intensity of
the pancreatic islets did not show different changes during
diazoxide treatment (Fig. 6B).3.6. Toxicity test
We investigated morphological changes, heartbeat, and body
length of the zebraﬁsh embryos to evaluate the toxicity of CK and
CD-CK. We did not observe morphological changes during CD-CK-
treatment. However, 20.0mM CK-treated zebraﬁsh had a mortality
rate of 100% (Fig. 7A). The GLM-treated zebraﬁsh had bent spines
and yolk sac edema at a 20.0mM concentration. Furthermore,
zebraﬁsh treated with 25.0mM GLM did not develop eyes or heads,
and also developed bent spines. At 2 dpt, there was no signiﬁcant
difference between CK- and CD-CK-treated zebraﬁsh in the heart-
beat and body length, compared to the normal group (Figs. 7Be7E).3.7. Toxicity of CK and CD-CK in MLS-EGFP
To evaluate mitochondrial changes due to CK and CD-CK, MLS-
EGFP zebraﬁsh larvaewere treatedwith 20mMCK and 20mMCD-CK.
The digestive system size of the CK-treated group was signiﬁcantly
decreased by 36.43% (p ¼ 0.0029), compared to the normal group.
The CD-CK-treated group was signiﬁcantly decreased by 23.57%
(p ¼ 0.0076), compared to the normal group. There was also a
signiﬁcant size difference in the digestive system between the CK
and CD-CK-treated groups, whereby the CK-treated group size was
decreased by 16.82% (p ¼ 0.0335) relative to the CD-CK-treated
group (Figs. 8A and 8B).
Fig. 6. The effects of b-cyclodextrin included in compound K (CD-CK) and CK (compound K) with diazoxide (DZ) in alloxan-induced pancreatic islet-damaged zebraﬁsh. (A) The size
change in the pancreatic islets in each group. (B) Fluorescence intensity analysis in the pancreatic islets of the zebraﬁsh. (C) Representative ﬁnal pancreatic islet images of the
normal (NOR), alloxan (AX), DZ, CK, CK with DZ, CD-CK, and CD-CK with DZ groups. Pancreatic islets are stained with 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose. The white arrow indicates the location of pancreatic islet. Scale bar ¼ 100 mm. ## p < 0.01, ### p < 0.001 compared to normal. * p < 0.05, ** p < 0.01, ***
p < 0.001 compared to alloxan. þþ p < 0.01.
J Ginseng Res 2017;41:103e112108The digestive system of the CK-treated group (mean number of
pixels ¼ 131; p ¼ 0.0018 and p ¼ 0.0002, respectively) had
signiﬁcantly decreased ﬂuorescence intensity, compared to the
normal group (the mean count of pixels ¼ 184) and the CD-CK-
treated group (the mean count of pixels ¼ 174) (Figs. 8A and
8C). These results indicate that CK decreased the expression of
mitochondria in the digestive system of treated zebraﬁsh. In
addition, CD-CK suppressed the mitochondrial damage incurred
by CK alone.
3.8. The TUNEL assays of CK- and CD-CK-treated digestive systems
in zebraﬁsh larvae
We examined apoptosis of the digestive system using the
TUNEL assay. The TUNEL staining of the digestive system showed
apoptotic cells in the CK- and CD-CK-treated zebraﬁsh larvae.
There were differences in the TUNEL-positive apoptotic cells. The
CK-treated zebraﬁsh larvae had an increased number of TUNEL-
positive cells, compared to the CD-CK-treated zebraﬁsh larvae
(Figs. 8D and 8E).
3.9. The LC50 values of CK and CD-CK
To evaluate LC50, we investigated mortality related to CK and
CD-CK in zebraﬁsh. Zebraﬁsh were treated with CK and CD-CK
at six different concentrations. The LC50 values of CK and CD-
CK were calculated at 14.24mM and 20.68mM, respectively
(Fig. 9).3.10. Therapeutic index
The TI of CK and CD-CKwere calculated by LC50/EC50. The TI is an
index of drug safety: safer drugs have a higher TI. The TI of CK and
CD-CK were calculated at 1.98 and 9.58, respectively (Fig. 10).4. Discussion
In our study, CD included in CK (CD-CK) enhanced bioavailability
through recovery of pancreatic islet damage in an alloxan-induced
diabetes zebraﬁsh model. Alloxan causes pancreatic b-cell necrosis,
which decreases b-cell mass, blocks insulin secretion, and thereby
induces diabetes [26e28]. We previously reported a decreased size
in the pancreatic islets and b-cells in alloxan-induced diabetic
zebraﬁsh, which veriﬁed zebraﬁsh as a diabetes model [29]. We
therefore used alloxan-induced diabetes zebraﬁsh and treated
them with GLM, CD, CD-CK, and CK. Glimepiride was the positive
control because it promotes insulin secretion by closing KþATP
channels and permits calcium (Ca2þ) inﬂow [24]. These processes
involve glucose utilization at the cellular level and regulate blood
glucose level in various tissues [30]. Compound K shows antidia-
betic activity by insulin secretion in b-cells, which acts on the KþATP
channels and improves insulin sensitivity [13]. The CK-treated
group showed recovery of damaged pancreatic islets and the CD-
CK-treated group exhibited a signiﬁcantly higher recovery,
compared to the CK-treated group, and improves the antidiabetic
effect of CK. This ﬁnding is consistent with previous CK treatment
results in type 2 diabetic mice and MIN6 b-cells [31].
Fig. 7. The toxicity of compound K (CK), b-cyclodextrin included in compound K (CD-CK), and glimepiride (GLM), based on zebraﬁsh embryo testing. (A) Comparison of the toxicity
results of CK, CD-CK, and GLM on zebraﬁsh embryonic development. The data are 2 d post-treatment (dpt) statistics. (B) The heartbeat/min in zebraﬁsh treated with CK at 2 dpt. (C)
The heartbeat/min in zebraﬁsh treated with CD-CK at 2 dpt. (D) The body length of zebraﬁsh treated with CK at 2 dpt. (E) The body length of zebraﬁsh treated with CD-CK at 2 dpt.
ND, not determined.
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Fig. 8. The toxicity of compound K (CK) and b-cyclodextrin included in compound K (CD-CK) in enhanced green ﬂuorescent protein (EGFP) expression fused to the mitochondrial
localization sequence (MLS) of zebraﬁsh COXVIII (MLS-EGFP) and TUNEL assays of CK- and CD-CK-treated digestive systems in zebraﬁsh larvae. (A) Representative whole zebraﬁsh
images. The red dotted line indicates the digestive system. Scale bar ¼ 100 mm. (B) Size of the digestive system analysis. (C) The ﬂuorescence intensity analysis. (D) The white arrow
indicates the location of apoptosis in the digestive system. Scale bar ¼ 50 mm. (E) Quantiﬁcation of TUNEL-positive apoptosis cells. TUNEL, TdT-UTP nick end labeling. ** p < 0.01
compared to the normal (NOR) group. *** p < 0.001. þ p < 0.05.
J Ginseng Res 2017;41:103e112110Based on these results, we investigated the pathway of insulin
secretion by modulating KATP channels. Closure of the KATP chan-
nels leads to membrane depolarization, the opening of voltage-
gated Ca2þ channels, and Ca2þ inﬂow and increase, which result
in insulin secretion [32,33]. Many diabetic models use diazoxide to



















Fig. 9. The LC50 of zebraﬁsh embryos exposed to compound K (CK) and b-cyclodextrin
included in compound K (CD-CK) for 48 h. The LC50 of CK was 14.24mM. The LC50 of CD-
CK was 20.68mM. Conc., concentration; EC50, 50% effective concentration; LC50, 50%
lethal concentration.induced diabetic mice and zebraﬁsh [29,34]. Compound K in-
creases insulin secretion by the KATP channel pathway in HIT-T15
cells, which have decreased insulin secretion with cotreatment
with diazoxide [13]. Therefore, we investigated how CD-CK
enhanced insulin secretion in diabetic zebraﬁsh using diazoxide
and CD-CK with diazoxide cotreated zebraﬁsh exhibiting signiﬁ-
cantly decreased pancreatic islet size, compared to CD-CK-treated
zebraﬁsh. These results suggest that CD-CK may stimulate insulin
secretion by closing KATP channels in pancreatic b-cells.
To verify the improved bioavailability of CD-CK, we investigated
the EC50 in the recovery effect on alloxan-related pancreatic islet
damage because CD-included compounds remove toxicity and in-
crease the rate of compound absorption [19,21]. The EC50 value of
CD-CK was 2.158mM, which showed that CD-CK has a recovery ef-
fect on damaged pancreatic islets at lower concentrations,
compared to CK alone (EC50 value 7.221mM). In addition, the
heartbeat and body length of CD-CK- and CK-treated zebraﬁsh
indicated no toxicity. We also calculated the LC50 by the zebraﬁsh
survival rate. Our results demonstrated that CD-CK had better
antidiabetic effects and lower toxicity, compared to CK, with LC50
values 20.68mM and 14.24mM, respectively.
Systematic toxicity of CK has not been reported; however, in a
subchronic toxicity study [22], CK showed possible hepatotoxicity.
In addition, CK cytotoxicity against tumor cells has been reported
[23]. The relationship between the EC50 and LC50 can be calculated
as the TI, which was used in quantitative comparisons of drugs as
the ratio of LC50 to EC50 [35]. The larger the TI, the safer the drug.
However, if the TI is small, the drug must be dosed carefully and the
patient receiving the drug should be monitored closely for any
signs of drug toxicity [35]. In this study, we demonstrated that CD-
CK is a safer drug, relative to CK, through the TI.
Fig. 10. The therapeutic index (TI) of compound K (CK) and b-cyclodextrin conjugated with compound K (CD-CK). The TI of CK and CD-CK was 1.98 and 9.58, respectively. Conc.,
concentration; EC50, 50% effective concentration.
Y.H. Nam et al / b-cyclodextrin compound K in zebraﬁsh 111The mechanism for CK toxicity is by mitochondrial damage.
Mitochondria are very sensitive to endogenous and exogenous
environmental stresses such as toxicants, iatrogenic medications,
immune activation, and metabolic disorders [36]. For CD-CK, the
expression of mitochondria was not changed, compared to the
control, but the CK-treated zebraﬁsh showed decreased mito-
chondrial expression. Therefore, CK toxicity may be related to
mitochondrial damage. In addition, the TUNEL assays showed
increased apoptosis in the digestive system of CK-treated zebraﬁsh.
Such aberrant apoptosis may contribute to the consequent
morphologic anomalies and damage of mitochondria in CK-treated
animals.
In conclusion, CD-CK inclusion complexes exhibit improved
solubility. We determined enhanced antidiabetic efﬁcacy and
lowered toxicity of CD-CK relative to CK treatment alone.Conﬂicts of interest
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